Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 30, 2025Journal of Clinical MedicineOpen Access

Pharmacogenetic Implications for Antidepressant Therapy in Major Depression: A Systematic Review Covering 2019–2024

View Full Paper
Ask AI
Bookmark
Share

Authors

AFAnna FornagueraMMMarta Miarons

Discussion

Loading...

Member takes

Overview

Systematic review shows pharmacogenetic factors impact antidepressant response in major depression, suggesting personalized prescribing may enhance outcomes.

Key Points

  • Genetic variants like CYP2C19 and CYP2D6 significantly influence antidepressant efficacy and safety.
  • Among 793 abstracts screened, 29 studies with nearly 40,000 participants were analyzed for pharmacogenetic data.
  • Poor metabolizers of CYP2C19 had higher SSRI plasma levels, leading to more adverse effects.
  • Combinatorial pharmacogenetic testing was more predictive of treatment outcomes than single-gene testing.

Cite This Study

Fornaguera et al. (2025) studied this question.

synapsesocial.com/papers/689a0945e6551bb0af8cedd8https://doi.org/10.3390/jcm14145102
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Pharmacogenetics and the Response to Antidepressants in Major Depressive Disorder2025
  2. 2Major Depressive Disorder (MDD), Pharmacogenomics, Antidepressant Therapy, Personalized Medicine, CYP2D6, CYP2C192025 · 1 citations
  3. 3Pharmacogenetics of antidepressant response: a focused review on CYP2C19, CYP2D6, SLC6A4, and HTR2A polymorphisms2026 · 2 citations
  4. 4Pharmacogenetic testing for selection of antidepressant treatment2024
  5. 5Pharmacogenomics for stratified antidepressant treatment in major depressive disorder: evidence, limits and a roadmap for clinical use2026